相关实验视频

Updated: Jul 2, 2025

Mixed Primary Cultures of Murine Small Intestine Intended for the Study of Gut Hormone Secretion and Live Cell Imaging of Enteroendocrine Cells

Mixed Primary Cultures of Murine Small Intestine Intended for the Study of Gut Hormone Secretion and Live Cell Imaging of Enteroendocrine Cells

Published on: April 20, 2017

在小鼠胃中鉴定葡萄糖类-1 (GLP-1) 的鉴定

Manami Otsuka¹, Jin Huang¹, Toru Tanaka²

¹Area of Regulatory Biology, Division of Life Science, Graduate School of Science and Engineering, Saitama University, 255 Shimo-ohkubo, Sakura-ku, Saitama, 338-8570, Japan.

Biochemical and biophysical research communications

|February 28, 2024

概括

这项研究确定了小鼠胃中产生葡萄糖类-1 (GLP-1) 的细胞,在体内发现表达率高于体内. 胃GLP-1的产生似乎与肠道中的不同调节.

科学领域:

内分泌学在内分泌学.
胃肠病学胃肠病学
分子生物学分子生物学

背景情况:

类似葡萄糖-1 (GLP-1) 是一种关键的内激素,主要在肠道L细胞中产生.
最近的研究表明,大鼠和人类的胃GLP-1存在,但它在小鼠中的作用尚未被探索.
了解胃GLP-1对于阐明其全部生理功能至关重要.

研究的目的:

为了识别小鼠胃中的GLP-1生产细胞.
研究小鼠胃粘膜内GLP-1生产的局部化和调节.
将胃GLP-1表达机制与肠道L细胞进行比较.

主要方法:

在小鼠胃体和肠道中对前葡萄糖的mRNA水平进行定量分析.
免疫组织化学和双重免疫光学用于识别和定位GLP-1免疫反应细胞.
在体外研究中,使用用TGR5激动剂治疗的SG-1细胞.
在TGR5激动剂的使用后,胃前葡萄糖 mRNA的体内评估.

主要成果:

在胃体中,前益格卢卡贡mRNA和GLP-1免疫反应细胞比胃体更丰富.
产生GLP-1的细胞部分同时表达体静止素,但不表达格林或胃素.
治疗TGR5激素治疗减少了SG-1细胞和胃体体内体内的前前葡萄糖mRNA.
胃GLP-1mRNA水平在体内被TGR5激动剂降低,但不是 antrum.

结论:

这项研究首次证实了小鼠胃内GLP-1的产生.
胃GLP-1表达主要局限于体内,与肠道L细胞相比,具有不同的调节机制.
这些发现表明胃GLP-1的新角色及其通过TGR5信号传递等途径的调节.

关键词:

这就是GLP-1.预前葡萄糖是什么?胃胃是指胃的部分.在TGR5中,TGR5是TGR5.

更多相关视频

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis

Published on: May 12, 2019

Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine

Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine

Published on: February 26, 2019

相关概念视频

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...